臺灣博碩士論文加值系統

在急性或慢性B型肝炎病毒感染中，乙型轉型成長因子是主要被誘發出的細胞素之一。除此之外，乙型轉型成長因子在細胞功能以及免疫反應的調控上扮演重要角色。在本研究的第一部份，為了研究乙型轉型成長因子在體外培養中對B型肝炎病毒複製的影響。我們利用重組腺病毒載體表現乙型轉型成長因子在穩定產生B型肝炎病毒顆粒之細胞株上。實驗結果證乙型轉型成長因子能夠在正於旺盛分裂的細胞株上減少細胞質中的B型肝炎病毒顆粒以及分泌於細胞培養液中之B型肝炎病毒顆粒。 第二部份的實驗中，為了研究乙型轉型成長因子在活體中對B型肝炎病毒複製的影響，我們進一步利用重組腺病毒載體表現乙型轉型生長因子在B型肝炎基因轉殖小鼠中。我們證明乙型轉型生長因子能夠減少在轉殖小鼠肝臟細胞中的B型肝炎病毒顆粒。然而乙型轉型生長因子對於乙型肝炎基因轉殖小鼠循環內的病毒顆粒並無抑制效應。

Transforming growth factor-beta1 (TGF-β1) is one of the major secreted cytokines in patients with acute or chronic HBV infection. Additionally, TGF-β1 plays an important role in regulation of cellular functions and immune responses. In first part of this study, we expressed TGF-β1 via recombinant adenovirus in HBV-producing stable cell lines to study effects of TGF-β1 on HBV replication in vitro. The results demonstrated that the effects of TGF-β1 could reduce cytoplasmic HBV nucleocapsids, and secreted HBV particles in the actively dividing HBV-producing cell lines. In the second part of this study, we further expressed TGF-β1 via recombinant adenovirus in HBV-transgenic mice to study the effect of TGF-β on HBV replication in vivo. We demonstrated that TGF-β1 could reduce cytoplasmic nucleocapsids in livers of HBV-transgenic mice in a dose dependent manner. However, TGF-β1 could not reduce HBV particles in the plasma of HBV-transgenic mice.

Abstract............ .........2

Introduction..................4

Material and method...........12

Results.......................20

Dissussion....................30

Reference.....................35

Figures.......................39

1. Rehermann, B. & Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5, 215-29 (2005).
2. Kao, J.H. & Chen, D.S. Global control of hepatitis B virus infection. Lancet Infect Dis 2, 395-403 (2002).
3. Seeger, C. & Mason, W.S. Hepatitis B virus biology. Microbiol Mol Biol Rev 64, 51-68 (2000).
4. Blumberg, B.S. Hepatitis B virus and the control of hepatocellular carcinoma. IARC Sci Publ, 243-61 (1984).
5. Fasani, P. et al. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 29, 1704-7 (1999).
6. Lin, T.M., Tsu, W.T. & Chen, C.J. Mortality of hepatoma and cirrhosis of liver in Taiwan. Br J Cancer 54, 969-76 (1986).
7. Chan, C.Y., Lee, S.D. & Lo, K.J. Legend of hepatitis B vaccination: the Taiwan experience. J Gastroenterol Hepatol 19, 121-6 (2004).
8. Guidotti, L.G. et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 284, 825-9 (1999).
9. Cavanaugh, V.J., Guidotti, L.G. & Chisari, F.V. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J Virol 72, 2630-7 (1998).
10. McClary, H., Koch, R., Chisari, F.V. & Guidotti, L.G. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 74, 2255-64 (2000).
11. Wieland, S.F., Guidotti, L.G. & Chisari, F.V. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 74, 4165-73 (2000).
12. Guidotti, L.G. et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4, 25-36 (1996).
13. Kakimi, K., Lane, T.E., Chisari, F.V. & Guidotti, L.G. Cutting edge: Inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver. J Immunol 167, 6701-5 (2001).
14. Cavanaugh, V.J., Guidotti, L.G. & Chisari, F.V. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 71, 3236-43 (1997).
15. Kimura, K., Kakimi, K., Wieland, S., Guidotti, L.G. & Chisari, F.V. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 76, 10702-7 (2002).
16. Flisiak, R., Prokopowicz, D., Jaroszewicz, J. & Flisiak, I. Plasma transforming growth factor-beta(1) in acute viral hepatitis. Med Sci Monit 11, CR304-308 (2005).
17. Shirai, Y. et al. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 73, 2275-9 (1994).
18. Khalil, N. TGF-beta: from latent to active. Microbes Infect 1, 1255-63 (1999).
19. Gentry, L.E. & Nash, B.W. The pro domain of pre-pro-transforming growth factor beta 1 when independently expressed is a functional binding protein for the mature growth factor. Biochemistry 29, 6851-7 (1990).
20. Sales, V.L. et al. Transforming growth factor-beta1 modulates extracellular matrix production, proliferation, and apoptosis of endothelial progenitor cells in tissue-engineering scaffolds. Circulation 114, I193-9 (2006).
21. McKarns, S.C., Schwartz, R.H. & Kaminski, N.E. Smad3 is essential for TGF-beta 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J Immunol 172, 4275-84 (2004).
22. Ahmadzadeh, M. & Rosenberg, S.A. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 174, 5215-23 (2005).
23. Oida, T., Xu, L., Weiner, H.L., Kitani, A. & Strober, W. TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling. J Immunol 177, 2331-9 (2006).
24. Hahn, B.H., Singh, R.P., La Cava, A. & Ebling, F.M. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J Immunol 175, 7728-37 (2005).
25. Gressner, A.M., Weiskirchen, R., Breitkopf, K. & Dooley, S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 7, d793-807 (2002).
26. Kakumu, S. et al. Effect of recombinant human transforming growth factor beta 1 on immune responses in patients with chronic hepatitis B. Liver 13, 62-8 (1993).
27. McClary, H., Koch, R., Chisari, F.V. & Guidotti, L.G. Inhibition of hepatitis B virus replication during schistosoma mansoni infection in transgenic mice. J Exp Med 192, 289-94 (2000).
28. Chou, Y.C. et al. Transforming growth factor-beta1 suppresses hepatitis
B virus replication primarily through transcriptional inhibition of pregenomic RNA. Hepatology (2007).
29. Dandri, M., Volz, T.K., Lutgehetmann, M. & Petersen, J. Animal models for the study of HBV replication and its variants. J Clin Virol 34 Suppl 1, S54-62 (2005).
30. Walter, E., Keist, R., Niederost, B., Pult, I. & Blum, H.E. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 24, 1-5 (1996).
31. Yang, P.L., Althage, A., Chung, J. & Chisari, F.V. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A 99, 13825-30 (2002).
32. Takehara, T. et al. Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication. J Hepatol 44, 267-74 (2006).
33. Guidotti, L.G., Matzke, B., Schaller, H. & Chisari, F.V. High-level hepatitis B virus replication in transgenic mice. J Virol 69, 6158-69 (1995).
34. Larkin, J. et al. Hepatitis B virus transgenic mouse model of chronic liver disease. Nat Med 5, 907-12 (1999).
35. Guilhot, S., Guidotti, L.G. & Chisari, F.V. Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism. J Virol 67, 7444-9 (1993).
36. Sime, P.J., Xing, Z., Graham, F.L., Csaky, K.G. & Gauldie, J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 100, 768-76 (1997).
37. Vallance, B.A. et al. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol 289, G116-28 (2005).
38. Luo, X. et al. Systemic transforming growth factor-beta1 gene therapy induces Foxp3+ regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice. Transplantation 79, 1091-6 (2005).
39. Biermer, M., Puro, R. & Schneider, R.J. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. J Virol 77, 4033-42 (2003).
40. Wieland, S.F., Eustaquio, A., Whitten-Bauer, C., Boyd, B. & Chisari, F.V. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A 102, 9913-7
(2005).
41. Pasquetto, V., Wieland, S.F., Uprichard, S.L., Tripodi, M. & Chisari, F.V. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 76, 5646-53 (2002).
42. Coffey, R.J., Jr., Kost, L.J., Lyons, R.M., Moses, H.L. & LaRusso, N.F. Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. J Clin Invest 80, 750-7 (1987).
43. Guidotti, L.G., Guilhot, S. & Chisari, F.V. Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways. J Virol 68, 1265-70 (1994).
44. Bessis, N., GarciaCozar, F.J. & Boissier, M.C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 11 Suppl 1, S10-7 (2004).
45. Worgall, S., Wolff, G., Falck-Pedersen, E. & Crystal, R.G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 8, 37-44 (1997).
46. Murata, T. et al. Suppression of hepatitis C virus replicon by TGF-beta. Virology 331, 407-17 (2005).
47. Bartholomeusz, A. & Locarnini, S. Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype. Hepatology 34, 432-5 (2001).
48. Uprichard, S.L., Wieland, S.F., Althage, A. & Chisari, F.V. Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci U S A 100, 1310-5 (2003).
49. Krastev, Z.A. The "return" of hepatitis B. World J Gastroenterol 12, 7081-6 (2006).